NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDAflibercept 114.3 mg/1 ml (equiv. to 8mg) Eylea®
(Intravitreal Injection ) 		Eye, Subfoveal choroidal neovascularisation, 11.08.02
REDAflibercept 40mg/1mL Yesafili®
(Intravitreal Injection ) 		Eye, Subfoveal choroidal neovascularisation, 11.08.02
Non Formulary items found
Status Description Section
 Aflibercept Zaltrap® Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Aflibercept Aflibercept [Specialist Drug] Eye, Macular Oedema, Retinopathy Of Prematurity, Antineoplastic Drugs Antineoplastics, Other
Aflibercept Aflibercept [Specialist Drug] Eye, Macular Oedema, Retinopathy Of Prematurity, Antineovascularisation Drugs Vascular Endothelial Growth Factor Inhibitors
Aflibercept Aflibercept [Specialist Drug] Eye, Retinal Disorders, Macular Degeneration, Antineoplastic Drugs Antineoplastics, Other
Aflibercept Aflibercept [Specialist Drug] Eye, Retinal Disorders, Macular Degeneration, Antineovascularisation Drugs Vascular Endothelial Growth Factor Inhibitors
Aflibercept Aflibercept [Specialist Drug] Malignant Disease, Targeted Therapy Responsive Malignancy, Antineoplastic Drugs Antineoplastics, Other
Aflibercept Aflibercept [Specialist Drug] Malignant Disease, Targeted Therapy Responsive Malignancy, Antineovascularisation Drugs Vascular Endothelial Growth Factor Inhibitors
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA294: Macular degeneration (wet age-related) - aflibercept
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
NICE TA346: Aflibercept for treating diabetic macular oedema
NICE TA486: Aflibercept for treating choroidal neovascularisation